\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes HealthThe Innovative Health Initiative (IHI) is launching its first calls for proposal in late June. IHI has already published the draft information on the upcoming calls to give applicants additional time to build a consortium and prepare a strong proposal.
Between 10 and 23 June, IHI organises a series of webinars where potential applicants can learn about the call topics and to get in touch with potential project partners. All webinars will include time for questions and answers.
A first webinar on 10 June 2022 on IHI's rules and procedures will cover issues ranging from who is eligible to participate in the projects, who is eligible to receive funding, and new features in IHI.
Update on 23 June 2022: An extra webinar on 27 June (at 14:30) focusing on financial aspects of proposals has been added to the series.
More information, the full programme of webinars and registration on the event webpage.
All recordings and slides of the all webinars in the series are available here afterwards.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
